GoodRx Holdings Inc (GDRX) Actualités

GoodRx Unveils New E-commerce Platform, Launches with Opill®

First over-the-counter daily birth control pill now available to order via GoodRx’s new direct-to-consumer...

GoodRx Announces Exclusive Low Cash Price for QSYMIA®, the Leading Branded Once-Daily Oral Weight Management Medication for Adults

First weight loss medication with an exclusive low cash price available on the GoodRx platform GoodRx (Nasdaq: GDRX), the leading prescription...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Ronald E. Bruehlman Joins GoodRx Board of Directors

IQVIA CFO brings 39 years of healthcare and finance expertise to GoodRx GoodRx Holdings, Inc. (Nasdaq: GDRX) ("we," "us," "our," “GoodRx” or the...

GoodRx Announces New Affordability Programs for Menopause Hormone Therapies

New GoodRx research shows menopause medications have increased in price by over 50% over the last...

Form 4 - Statement of changes in beneficial ownership of securities

GoodRx Partnering with Retail Pharmacies to Deliver Pay-Over-Time Option Directly to Consumers

Approved users will now be able to select an Affirm payment plan for select medications directly on the GoodRx platform GoodRx (NASDAQ: GDRX...

GoodRx Announces Date for Third Quarter 2024 Earnings Release and Conference Call

GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading prescription savings platform in the U.S., today announced it will...

GoodRx Announces Lowest Discounted Cash Price at Retail Pharmacy Locations for neffy® (epinephrine nasal spray)

neffy is available in pharmacies this week and the lowest discounted cash price at retail pharmacies can be found exclusively at GoodRx neffy is...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities